GRACEcast Lung Cancer Video

Jul 31 2014 300 ep. 8 mins 221
GRACEcast Lung Cancer Video Podcast artwork

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

Jul 31 2014 4 mins  
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

Jul 27 2014 5 mins  
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

Jul 22 2014 2 mins  
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

Jul 17 2014 7 mins  
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

Jul 13 2014 7 mins  
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

Jul 08 2014 3 mins  
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

MET-Amplified Lung Cancer: A New Target for XALKORI?

Jul 03 2014 7 mins  
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

Jun 29 2014 4 mins  
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

FGFR and Its Role in Treating Squamous Cell Lung Cancer

Jun 25 2014 2 mins  
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

Jun 24 2014 11 mins  
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.